Cedars-Sinai Biomanufacturing Center

Name

Cedars-Sinai Biomanufacturing Center

Legal name

Cedars-Sinai Health System

Website

https://csbiomfg.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Cell Therapy Biomanufacturing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)

akta.pro secondary industry

Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA)

Keywords

• Cell therapy manufacturing
• IPSC biomanufacturing services
• CGMP contract manufacturing
• Stem cell repository
• Gene therapy production

Headquarters

HQ city

West Hollywood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Others

Revenue model

1. Cell Collection Products: Cell line product catalog offering iPSC lines, GMP iPSC lines, gene-modified iPSCs, neural cells, ESC lines available for order via online catalog with Material Transfer Agreement requirements.
2. Research and GMP Services: Contract research services including custom iPSC generation, PSC quality control and characterization, PBMC isolation and processing, biobanking and PSC thawing, and GMP manufacturing and quality control services for IND-enabling clinical trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cedars-Sinai Biomanufacturing Center (CBC) is a 22,000 sq ft cGMP biomanufacturing facility that maintains one of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, and differentiated cells, and provides contract research services (custom iPSC generation, PSC QC, PBMC processing, biobanking) along with cGMP-compliant manufacturing and quality control services for cell and gene therapy products intended for IND-enabling clinical trials.

Product overview

Cedars-Sinai Biomanufacturing Center (CBC) operates as a 22,000 square foot state-of-the-art biomanufacturing facility offering an integrated portfolio of stem cell products and contract research services. The core offering is its Cell Collection Repository—one of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, and differentiated cells (including neural cells, endothelial cells, and motor neuron precursors). Supporting this repository are two main service lines: Research Services (custom iPSC generation using footprint-free reprogramming, PSC quality control and characterization, PBMC isolation and processing, and biobanking/PSC thawing) and GMP Services (cGMP manufacturing of cell and gene therapy products including MCBs/WCBs, iPSC-derived cells, gene-edited therapies, and immunotherapies; plus GMP quality control with characterization testing, sterility/mycoplasma/endotoxin testing, flow cytometry, and ddPCR). The facility contains seven ISO 7 cGMP cleanroom production suites and specialized equipment including CliniMACS Prodigy instruments and clinical-grade cell sorters.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Collection Repository One of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, differentiated cells (including neural and endothelial cells), and related lines, available for order via online catalog and supplied under Material Transfer Agreement.
• Custom iPSC Generation Contract research service generating footprint-free induced pluripotent stem cells from human somatic tissues using non-integrating oriP/EBNA1 episomal plasmids.
• PSC Quality Control and Characterization Quality control and characterization testing services for pluripotent stem cell lines, including identity, viability, composition, activity, and stability assessments.
• PBMC Isolation and Processing PBMC isolation and processing services for downstream research and biobanking applications.
• Biobanking and PSC Thawing Biobanking services including stem cell banking, expansion of iPSC lines, and PSC thawing procedures.
• GMP Manufacturing Services cGMP-compliant biomanufacturing services for cell and gene therapy products, including manufacturing of MCBs and WCBs, autologous and allogeneic cell products, iPSC reprogramming, iPSC-derived cells, gene-edited therapies, retinal cells, cellular immunotherapies, NK cell therapies, and CAR T/TCR therapies, performed in seven ISO 7 cGMP cleanroom suites.
• GMP Quality Control Services GMP quality control services including cell bank characterization testing (identity, viability, composition, activity, stability), sterility, mycoplasma and endotoxin testing, flow cytometry, ddPCR, and custom QC method development and validation.

Quantifiable outcome

• One of the largest global repositories of induced pluripotent stem cells (iPSCs), embryonic stem cells, gene-modified iPSCs, and differentiated cells
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• BlueRock Therapeutics: Developer and manufacturer of iPSC-derived cell therapies, with engineered cell medicines for regenerative medicine. Most directly comparable as a specialized iPSC cell therapy developer with proprietary manufacturing capabilities.
• Century Therapeutics: Clinical-stage biotech developing iPSC-derived allogeneic cell therapies including CAR-T and NK cell programs. Comparable as a developer leveraging iPSC manufacturing for clinical-grade cell therapies.
• Roslin Cells (RoslinCT): Scottish CDMO specializing in iPSC-derived cell therapy manufacturing and clinical-grade cell banking. Directly comparable as a CDMO offering iPSC reprogramming, cell banking, and cGMP manufacturing services.
• WiCell (Wisconsin Cell Bank): Nonprofit stem cell bank and iPSC repository providing characterization and distribution services for academic and commercial clients. Directly comparable as a major iPSC repository and cell banking service.

Emerging players

• Cellares: Emerging cell therapy manufacturing company developing automated cell therapy manufacturing platforms. Comparable as a next-generation cell therapy manufacturing provider targeting biotech and academic clients.
• Cynata Therapeutics: Clinical-stage biotech developing iPSC-derived mesenchymal stem cell therapies. Comparable as a developer leveraging iPSC manufacturing for off-the-shelf cell therapy products.

Broad incumbents

• Lonza Cell & Gene Technologies: Global CDMO offering cell and gene therapy manufacturing services including iPSC-derived cell therapy production at industrial scale. Comparable as a cGMP cell therapy CDMO, but with far broader scale and global footprint than the Cedars-Sinai facility.
• Catalent Cell & Gene Therapy: Major CDMO providing cell therapy development, manufacturing, and analytical services. Directly comparable as a cGMP cell and gene therapy manufacturer serving biotech and academic clients with similar service portfolio.
• Thermo Fisher Scientific (Pharma Services / Patheon): Large-scale CDMO with cell and gene therapy manufacturing and viral vector services. Provides comparable cGMP manufacturing services but as part of a much broader pharma services portfolio.

Regional players

• Cell and Gene Therapy Catapult: UK-based cell and gene therapy accelerator with GMP manufacturing facilities and large-scale industrial centers. Comparable as a translational cell therapy CDMO but primarily serving UK and European markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CSBiomfgCenter
• LinkedInlinkedin.com/company/cedars-sinai-biomanufacturing-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cedars-Sinai Biomanufacturing Center